Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Anti-Inflammatory Treatment on Insulin Resistance in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~Age: Greater than 18 and less than 45 years.~Number: 44 completed studies (22 placebo, 22 Salsalate).~Sex: 22 Males and 22 Females.~BMI: Greater than or equal to 30 kg.m(2)~EXCLUSION CRITERIA:~* Age below 18 or above 45 years to minimize the risk of glucose clamp.~* Diabetes mellitus (as per 75 g OGTT, WHO 1999 criteria)~* Cardiovascular disease including: abnormal EKG, personal history of coronary heart disease;symptomatic angina pectoris or cardiac insufficiency as defined by NYHA; classification as functional class III or IV.~* Systolic blood pressure greater than 160mmHG and/or diastolic blood pressure greater than 100 mmHg and/or on antihypertensive therapy or resting heart rate greater than 90 bpm.~* Hematological disorder, including prolonged prothrombin time (normal range 10.9-12.9 sec) and partial thromboplastin time (24-36 sec) and thrombocytopenia (less than 150,000 mm(3)).~* Respiratory disease (including influenza, asthma)~* Allergies (including hay fever)~* Gastrointestinal (including peptic ulcer), hepatic or renal disease (ALT and AST greater than 3-fold above upper limit of normal range, creatinine greater than 1.3 mg/dl).~* Alcoholism, alcohol-induced autonomic neuropathy.~* Any endocrinological disorder, including hypopituitarism/pituitary dysfunctions or lesions, hypo/hyperthyroidism, insulinoma.~* CNS disease~* Psychosis or personal history of any psychiatric disorder.~* Taking medications within one month prior to beginning the study, including medications known to have pharmacological interactions with salicylates or that may affect insulin sensitivity and secretion (including salicylates, COX 1 and COX 2 inhibitors, warfarin, Beta-Blockers, phenothiazines, antidepressants, antiarrhythmic drugs, antimuscarinic drugs).~* Acute inflammation as assessed by history, physical and laboratory examination (subjects with C-reactive protein 2 standard deviations above the population mean will not be admitted). The population mean was calculated from subjects admitted at our research unit.~* Pregnant or lactating females or females on hormonal contraceptives.~* History of metabolic acidosis.~* Allergy to aspirin, other salicylates, or bleeding diathesis or currently on oral anticoagulants.~* Any current viral illness.~* Active cancer within 5 years prior to screening for the study.~* Positive urine drug screening test.~* Inability to provide informed consent.~* Smokers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Salsalate (Type: EXPERIMENTAL): Salsalate (3g/day) for 7 days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).